Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132882 | 0.96 | ALDH1A1 (0.42) | HPGDALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL3060452 | 0.94 | HPGD (0.48) | HPGDALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL8860937 | 0.92 | HPGD (0.52) | HPGDALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL2202337 | 0.85 | ALDH1A1 (0.41) | HPGDALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL3950467 | 0.85 | HPGD (0.52) | HPGDALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL4372871 | 0.83 | HPGD (0.56) | HPGDALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL3312314 | 0.79 | ALDH1A1 (0.42) | HPGDALDH1A1TSHRSMN1; SMN2LMNA | |
| SCHEMBL3913964 | 0.77 | HPGD (0.46) | HPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8655587 | 0.73 | HPGD (0.39) | HPGDALDH1A1TSHRHTTHSD11B1 | |
| SCHEMBL3911205 | 0.73 | HPGD (0.42) | HPGDALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927192-A1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1999-07-07 | — | — | EP | claimed |
| WO-1998011128-A1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1998-03-19 | — | — | WO | claimed |
| EP-1926721-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-04 | — | — | EP | disclosed |
| US-7977374-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-07-12 | — | — | US | disclosed |
| US-20090156591-A1 | Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
| EP-1926721-A2 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007029035-A2 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156591-A1 | Thiophene and Thiazole Substituted trifluoroethanone Derivatives as Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC2, HDAC11 | HPGD 1160/4885ALDH1A1 398/4885TSHR 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.